Eli Lilly is making Alzheimer's a major focus for its future innovations. The company is also expanding its specialty medicine offerings in...

Prices for generic semaglutide, a popular weight-loss drug, are expected to fall by more than half in the coming months. This sharp decline...

India’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...

Pfizer reported higher-than-expected sales and profit on Tuesday and said a patent extension for its Vyndamax heart drug and a recent favor...

Kailera Therapeutics shares surged 62.5% in their Nasdaq debut after raising $625 million in a U.S. IPO priced at the top end of its range....

PFE stock today: Pfizer's stock dipped despite strong fourth-quarter earnings. Investors reacted to the company's modest 2026 outlook. Decl...

Obesity, weight-loss medicines: Novo has been scrambling to keep pace in the obesity drug race it started, losing ground to rival Eli Lilly...

Metsera has accepted Pfizer's $10 billion acquisition offer. This ends a bidding war with rival Novo Nordisk. Pfizer will pay $86.25 per sh...

Pfizer is increasing its offer for Metsera. This comes after a judge rejected Pfizer's attempt to stop rival Novo Nordisk's bid. Pfizer's d...

A fierce bidding war is underway for Metsera, an obesity drug developer. Novo Nordisk has made a $10 billion offer, which Metsera considers...

Pfizer sued Metsera and Novo Nordisk, alleging Metsera breached its merger agreement by deeming Novo's $8.5 billion bid superior. Pfizer se...

Pfizer Inc. (NYSE: PFE) experienced a significant uptick in its stock price following two major announcements on September 30, 2025. Presid...

Stock Market boom for both companies' shares came as Pfizer said on Monday it would acquire drug developer Metsera in a deal valued at up t...

Pfizer is close to acquiring Metsera, an anti-obesity drug developer. The deal could be worth $7.3 billion. Pfizer will pay $47.50 per shar...

Pfizer halted development of its weight-loss pill, danuglipron, after liver injury concerns surfaced during trials, impacting its ambition ...

Pfizer has halted the development of its experimental weight-loss pill, danuglipron, following a trial participant's liver injury, which re...

Pfizer Inc. is shifting its research focus to diseases that have high potential for big profits and for treatment improvements, such as can...